Aptose Biosciences (APTO) has released an update to notify the public and investors about a regulation fd disclosure.
On January 26, 2024, the Registrant released a press statement. The information in the release, although attached to official documentation, is not to be considered “filed” under the Securities Exchange Act of 1934, nor is it to be incorporated by reference into any other filings, unless explicitly stated in such filings.
For further insights into APTO stock, check out TipRanks’ Stock Analysis page.
